• Cart


Adam Gwozdz, MD, PhD, MBAAdam Gwozdz, MD, PhD, MBA
Medical Director, Stryker Peripheral Vascular

The treatment of deep vein thrombosis (DVT) continues to evolve, yet an important clinical question remains: Does early thrombus removal improve outcomes compared with anticoagulation alone?

The DEFIANCE trial was designed to help answer that question.

DEFIANCE is a prospective, multicenter, randomized controlled trial comparing the ClotTriever System plus standard anticoagulation to conservative medical management with anticoagulation alone in patients with symptomatic unilateral iliofemoral DVT. Approximately 300 patients will be randomized 1:1, and outcomes will be followed for six months.

DEFIANCE is particularly important because it focuses on patient-centered clinical outcomes rather than procedural success alone. The primary endpoint uses a hierarchical “win ratio” that prioritizes treatment failure or escalation, followed by post-thrombotic syndrome (PTS) severity as measured by the Villalta scale at six months. The study also incorporates independent adjudication, core laboratory assessment of duplex ultrasound, and blinded assessment of PTS severity.

For clinicians caring for patients with proximal DVT, these questions matter. Anticoagulation prevents thrombus propagation and embolization, but it does not actively remove existing thrombus. At the same time, previous randomized studies of thrombolytic-based strategies have been limited by comparatively low rates of technical procedural success, with significant residual thrombus persisting in treatment arms despite the added bleeding risk. (REF 1 and 2).

Mechanical thrombectomy offers an alternative approach: removing thrombus without the use of thrombolytic drugs. Observational data, including the CLOUT registry, have provided encouraging evidence of safety, thrombus removal, and longer-term patient outcomes (REF 3). DEFIANCE builds on this foundation by providing randomized evidence directly comparing mechanical thrombectomy with anticoagulation alone.

As venous specialists, we need high-quality evidence to guide patient selection and treatment decisions. DEFIANCE is an important step toward determining whether an early interventional strategy can provide meaningful clinical benefits for patients with iliofemoral DVT.

The goal is simple: generate evidence that helps us make better treatment decisions for our patients.

AVF 2027 - Harmony in Venous Care February 27 - March 2 Grand Hyatt Nashville